PDF Cover

Plaque Modification and Removal Devices Market

The market for Plaque Modification and Removal Devices was estimated at $2.3 billion in 2024; it is anticipated to increase to $3.7 billion by 2030, with projections indicating growth to around $5.5 billion by 2035.

Report ID:DS1801033
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Medical Device
Plaque Modification and Removal Devices
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Plaque Modification and Removal Devices Market Outlook

Revenue, 2024

$2.3B

Forecast, 2034

$5.0B

CAGR, 2025 - 2034

8.4%

The Plaque Modification and Removal Devices industry revenue is expected to be around $2.4 billion in 2025 and expected to showcase growth with 8.4% CAGR between 2025 and 2034. The increasing need for plaque modification and removal equipment in the cardiovascular field is reflected in this vision of future development. Growing pressure on healthcare services due to rising levels of coronary artery disease and peripheral artery disease a result of increasing age and a higher incidence of diabetes and other conditions is driving this development. The increasing workload of treatments involving minimally invasive techniques for plaque removal and difficult to access arteries is strengthening the position of such angioplasty machines in vascular interventions. The atherectomy product region constitutes the most dominant sector in the Plaque Modification and Removal Devices market with sales estimated to reach 1.03 billion dollars in 2024, a testimony to the success of the devices in clinical settings for the intervention of high risk vascular conditions among cardiologists and vascular specialists. Advances in technology, accumulation of clinical data and their incorporation into treatment recommendations are maintaining the importance of the market and leading to cardiovascular devices becoming a more integral part of standard care for those with cardiovascular disease.

The range of Plaque Modification and Removal Devices, include various atherectomy devices with cutting and also scoring functions, cutting and scoring balloons, and also systems which use sound waves to break up plaque. These are used in endovascular procedures to either remove, break up or alter the plaque. This allows for smoother devices to be placed within the body, for more effective angioplasty and for stents to be put in the body in the most effective position. The main focus of this market is on conditions of the hearts blood vessels. These conditions are coronary artery disease and peripheral artery disease which together represent all applications. This is as more and more doctors seek to modify plaque in difficult to reach, calcified and long lesions that also split into two sections and cannot be treated by a balloon expansion procedure. A rise in demand is being witnessed due to the integration of Plaque Modification and Removal Devices with imaging technologies, which allow for high resolution intravascular imaging for the assessment of lesions. Additionally, a broader application of the Plaque Modification and Removal Devices in conjunction with drug coated balloons is taking place for the management of peripheral artery disease. This shift towards durable revascularization procedures is aimed at improving the long term patency of the arteries, reducing the need for repeat procedures and enhancing patient care.

Plaque Modification and Removal Devices market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2024-2034
Plaque Modification and Removal Devices Market Outlook

Market Key Insights

  • The Plaque Modification And Removal Devices market is projected to grow from $2.3 billion in 2024 to $5.0 billion in 2034. This represents a CAGR of 8.4%, reflecting rising demand across Plaque Disruption and Debulking, Treatment of Peripheral Artery Disease (PAD), and Coronary Intervention Procedures.

  • The competitive landscape of the market is shaped by companies such as Medtronic, Abbott and Boston Scientific.

  • The North American and Chinese markets will be the dominant sectors in the Plaque Modification and Removal Devices industry and are forecast to grow at an annual rate of 6.1% to 8.8% between 2024 and 2030.

  • These markets, namely South Africa, Saudi Arabia and Brazil, are expected to record the highest growth rate with a compound annual growth rate lying between 8.1% and 10.5%.

  • A significant trend anticipated to boost the Plaque Modification and Removal Devices market value by $341 million by 2030 is the shift towards minimally invasive procedures.

  • The market for Plaque Modification and Removal Devices is forecast to expand by $2.8 billion between 2024 and 2034 with the sector for use in Peripheral Artery Disease Applications expected to capture the largest market share.

  • With

    synergistic impact of rising cardiovascular disease burden and technological innovation, and

    Shifting Preference Toward Minimally Invasive and Outpatient Cardiovascular Interventions, Plaque Modification And Removal Devices market to expand 124% between 2024 and 2034.

plaque modification and removal devices market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Plaque Modification and Removal Devices - Country Share Analysis

Opportunities in the Plaque Modification and Removal Devices

In Western and Northern Europe various service and capacity constraints are promoting the transfer of complex procedures to out patient surgical centres. Such movements demand smaller and simpler plaque modification and removal equipment. In particular, devices which cause total occlusion but shorten the time taken for the procedure and reduce the amount of contrast which is also used are particularly appealing for patients who are elderly and have multiple diseases. The worldwide CTO device market is forecast to grow from $0.31 billion in 2012 to $0.44 billion by 2030. It is expected that European CTO treatments will have the greatest annual increase in volume of any region.

Growth Opportunities in North America and Europe

The primary motivation for the adoption of Plaque Modification and Removal Devices in North America is complex coronary interventions that occur at high volumes. This situation makes coronary artery disease the fields most significant application. As a result, atherectomy devices with advanced technology and intravascular lithotripsy have become the key to differentiating products. Key region's of opportunity for the company are the outpatient cath lab, where minimally invasive plaque modification procedures can be increased, as well as the integration of intravascular imaging to guide stent placement so as to improve its efficiency. Additionally, their product portfolio needs to be tailored for use in those with high risk calcified lesions, such as diabetics and the elderly. Medical equipment companies producing products to aid in cardiovascular treatments face a highly competitive market where they compete against other large cardiovascular device and endovascular companies. These firms compete on clinical outcomes, the ease of delivery of devices and the compatibility with either drug coated balloon or drug eluting stent technology; new companies operating in this field have to focus on health economics data which is robust, crossing profiles that are streamlined, and new mechanisms of action. In the region the main drivers for demand are a high usage of devices used in the removal of coronary artery plaque which is guided by best medical practice, the strong reimbursement of the treatment by the endovascular method, the rapid adoption of catheter technology platforms, and a programme focus on reducing the number of procedures that have to be carried out again. There is also a goal to reduce the time required for each procedure in advanced PCI treatments.
The procedure of plaque modification and removal is of similar significance in Europe for both peripheral artery disease and coronary artery disease. The interest in peripheral artery disease is rising due to the ageing European population and a strong interest in limb saving techniques particularly below the knee. The key opportunities lie in cost effective plaque modification techniques suitable for various healthcare systems, expanding the usage of peripheral atherectomy devices alongside drug coated balloons and customising the product range for smaller vessel sizes and long lesions. The interplay between global medical device suppliers and regional endovascular specialists in the market has a profound effect on its dynamics. Technology value, real world clinical outcomes and the country's healthcare payment system have a significant bearing on purchasing decisions. A product that is applicable in both coronary and peripheral treatments is advantageous. Factors driving the demand for these products include the increasing number of patients being screened for peripheral arterial disease, a clinical push to reduce the number of amputations, the increasing use of minimally invasive endovascular procedures in favour of traditional surgery and the demand from hospitals for devices which allow for the treatment of patients on a day case basis without compromising safety or the long term success of the treatment.

Market Dynamics and Supply Chain

01

Driver: Synergistic Impact of Rising Cardiovascular Disease Burden and Technological Innovation

The escalating global prevalence of cardiovascular diseases, including coronary artery disease and peripheral artery disease, is also a primary growth catalyst for Plaque Modification and Removal Devices. Aging populations, sedentary lifestyles, and an increase in metabolic disorders like diabetes and obesity have also expanded the pool of patients requiring advanced plaque treatment options, driving demand for effective interventional tools. Simultaneously, rapid technological advancements in atherectomy systems, laser‑based ablation, intravascular lithotripsy, and integrated imaging technologies such as IVUS and OCT are also enhancing procedural precision and safety. These innovations not only improve clinical outcomes but also broaden the clinical applicability of minimally invasive procedures, enabling effective treatment of complex and heavily calcified lesions. The convergence of heightened disease incidence with continuous device improvement is also thus a powerful dual driver expanding adoption in hospitals, catheterization labs, and ambulatory care settings. 
Healthcare delivery trends are also increasingly favoring minimally invasive procedures with shorter recovery times, reduced risk profiles, and cost efficiencies. Atherectomy and other plaque modification techniques align with these preferences, enabling clinicians to treat lesions with less trauma than traditional open surgery. The growth of ambulatory surgical centers and outpatient labs further accelerates adoption, as compact, user‑friendly plaque removal devices allow same‑day discharge and more efficient use of resources. This shift supports broader procedural uptake beyond traditional hospital settings.
02

Restraint: High Cost Burden Coupled With Limited Reimbursement Coverage Hindering Adoption

The high price of Plaque Modification and Removal Devices and associated procedures presents a major market restraint, especially in cost‑sensitive regions. Advanced atherectomy and laser systems can add tens of thousands of dollars to a single intervention, deterring smaller hospitals and clinics from investing in these technologies due to budget constraints. In many emerging markets reimbursement policies lag behind clinical innovation, forcing providers and patients to absorb costs or opt for lower‑cost alternatives such as stenting or balloon angioplasty, thereby constraining revenue growth and device uptake.
03

Opportunity: Rapidly growing peripheral arterial disease population in the United States driving advanced atherectomy device demand and Underpenetrated coronary artery disease treatment markets in India and Southeast Asia accelerating intravascular lithotripsy adoption

The growing incidence of diabetes, smoking and obesity in the United States is adding to the number of people suffering from peripheral arterial disease. As a result, there is an unmet demand for devices that modify and remove plaque in the legs. This demand is particularly felt for complex procedures in the femoral and popliteal region's and below the knee. Increasingly, cath labs in hospitals are using atherectomy devices in limb salvage treatments which has led to atherectomy revenue reaching 1.03 billion dollars in the year 2024. It is predicted that this revenue will rise to 1.57 billion dollars by the year 2030 at a compound annual growth rate of 7.3%. This segment is predicted to be the fastest growing in the lower limb peripheral arterial device market. Atherectomy devices used in lower limb peripheral interventions are expected to drive this trend.
Growing populations in South East Asia and India with rising incomes have been shown to have higher rates of cardiovascular tests. This has uncovered a number of people with calcified coronary arteries in need of treatment. As a result, there is a growing demand for devices that remove or alter blockages in the arteries. The new intravascular lithotripsy devices allow for precise manipulation of arterial calcium with less damage to the artery. This fits in with the current trend of less invasive procedures. Furthermore, it appears that these new technologies will be reimbursed by health insurance. By 2030, the global intravascular lithotripsy market should reach a value of $1.35 billion, rising from $0.71 billion. It will be Asia Pacific coronary applications which will witness the fastest growth.
04

Challenge: Procedural Complexity, Safety Risks and Training Gaps Limit Market Expansion

Plaque modification procedures require specialized operator skills and carry procedural risks such as vessel perforation, distal embolization and restenosis that can influence clinician preference and patient outcomes. Healthcare facilities with limited trained staff may avoid adopting these devices, favoring more familiar interventions. This steep learning curve and safety concern can slow demand, particularly in lower‑volume centers where maintaining proficiency is challenging, ultimately reducing overall market penetration.

Supply Chain Landscape

1

Product R&D

Boston Scientific CorporationAbbottMedtronic
2

Device Manufacturing

Boston Scientific CorporationMedtronicBD
3

Distribution & Support

BDKoninklijke Philips N.V.Abbott
4

Clinical End-Use

HospitalsCardiac Catheterization LabsAmbulatory Surgical Centers
Plaque Modification and Removal Devices - Supply Chain

Use Cases of Plaque Modification and Removal Devices in Disruption & Debulking

Plaque Disruption and Debulking : Minimally invasive atherectomy systems are widely employed in the Plaque Disruption and Debulking application of the Plaque Modification and Removal Devices market to effectively remove atherosclerotic plaque and restore vessel patency. These devices, including directional, rotational, orbital, and laser atherectomy tools, are primarily used in hospitals by interventional cardiologists and vascular surgeons. Key market leaders such as Boston Scientific, Medtronic, Abbott, and Cardiovascular Systems Inc. capitalize on advanced technology, broad product portfolios, and global distribution to provide precise and safe plaque management.
Treatment of Peripheral Artery Disease (PAD) : In the Treatment of Peripheral Artery Disease, Plaque Modification and Removal Devices are primarily atherectomy systems used by interventional cardiologists and vascular surgeons to mechanically debulk atherosclerotic plaque in blocked peripheral arteries, particularly in the legs, improving blood flow and reducing symptoms such as claudication. These include directional, rotational, orbital, and laser atherectomy devices, which enable precise, minimally invasive plaque removal and facilitate subsequent angioplasty or stenting with better outcomes and faster recovery. Leading market players such as Boston Scientific, Medtronic, Abbott and Philips hold strong positions with comprehensive atherectomy portfolios backed by clinical evidence and wide adoption in hospitals and specialty centers, while smaller innovators like Avinger and CardioFlow bring niche technologies that enhance procedural efficiency and versatility in complex PAD lesions.
Coronary Intervention Procedures : In Coronary Intervention Procedures, Plaque Modification and Removal Devices such as rotational, laser and orbital atherectomy systems are predominantly used to debulk and reshape calcified atherosclerotic lesions during complex percutaneous coronary interventions (PCIs), enhancing vessel preparation for balloon angioplasty and stenting. These devices, employed mainly in hospitals and cardiac catheterization labs, offer improved lesion accessibility and procedural success in heavily calcified coronary artery disease. Leading players like Boston Scientific, Philips, Cardiovascular Systems, Medtronic and Abbott dominate this space with advanced, precision‑engineered platforms and strong clinical adoption globally.

Recent Developments

Recent strategic moves in the Plaque Modification and Removal Devices space reflect consolidation and innovation, notably Boston Scientific’s acquisition of Bolt Medical and Abbott’s launch of a U.S. intravascular lithotripsy clinical trial for calcified coronary lesions. Boston Scientific’s integration of IVL technology expands its calcium modification portfolio and strengthens its position in percutaneous coronary intervention markets. Meanwhile, Abbott’s investigational IVL system advances interventional cardiology research by addressing procedural challenges in severe calcification. A key market trend is the rising adoption of minimally invasive vascular therapies and advanced imaging‑guided plaque treatment, improving procedural precision and patient outcomes.

January 2025 : Boston Scientific Corporation announced a definitive agreement to acquire Bolt Medical, Inc., a developer of an advanced intravascular lithotripsy platform for treating coronary and peripheral arterial disease. This strategic acquisition aims to strengthen BSX’s presence in calcium modification therapies that complement traditional atherectomy systems, expanding its portfolio in minimally invasive plaque treatment technologies.
September 2024 : AngioDynamics, Inc. secured CE Mark regulatory approval in September 2024 for its Auryon laser atherectomy system in Europe. This approval enables the commercial launch of the technology for treating peripheral artery disease lesions, including complex and calcified occlusions, expanding its market reach beyond U.S. use.
January 2024 : AngioDynamics announced that the FDA cleared the Auryon XL radial access catheter for use with its Auryon Atherectomy System in PAD treatment, expanding procedural access options and supporting broader adoption in clinical practice.

Impact of Industry Transitions on the Plaque Modification and Removal Devices Market

As a core segment of the Medical Device industry, the Plaque Modification and Removal Devices market develops in line with broader industry shifts. Over recent years, transitions such as Shift Towards Minimally Invasive Procedures and Integration of AI‑Enabled Navigation and Imaging Technologies have redefined priorities across the Medical Device sector, influencing how the Plaque Modification and Removal Devices market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Shift Towards Minimally Invasive Procedures

The growth in demand for minimally invasive surgery procedures is expected to be a key factor behind the growth of the Plaque Modification and Removal Devices market, driving expansion of $341 million by the end of 2030. In response to healthcare policies which are cutting back on lengthy hospital stays plus also trying to limit blood loss and promote quicker recovery for patients, companies manufacturing minimally invasive plaque removal technologies are noticing increased interest in their products. The use of these devices produces superior clinical results and also greater safety in procedures undertaken, at the same time helping hospitals to be cost efficient and helping to reduce healthcare costs. The trend is being driven by the increasing use of interventional cardiology equipment in hospitals and in out patient care facilities. These factors are bringing plaque modification and removal using minimally invasive techniques to the forefront of medical strategy for both providers and manufacturers, driving sustainable growth in the global Plaque Modification and Removal Devices market.
02

Integration of AI‑Enabled Navigation and Imaging Technologies

Another pivotal transition in this market is the incorporation of artificial intelligence and advanced imaging guidance into plaque modification workflows, improving lesion assessment and procedural precision. AI‑enhanced platforms now work alongside intravascular ultrasound and optical coherence tomography, enabling real‑time plaque characterization and optimal device selection. The impact extends into imaging and software sectors, prompting investment in AI algorithms and edge computing solutions tailored for catheterization labs. This convergence enhances clinical outcomes, reduces restenosis rates, and strengthens adoption of plaque modification procedures in both hospital and outpatient settings, ultimately expanding the value proposition of interventional cardiology suites and diagnostic imaging services.